糖尿病及急性冠状动脉综合征患者ApoB与ApoA1比值测定的临床意义

姜伟超, 张德太, 张科, 等. 糖尿病及急性冠状动脉综合征患者ApoB与ApoA1比值测定的临床意义[J]. 临床血液学杂志, 2013, 26(12): 837-840.
引用本文: 姜伟超, 张德太, 张科, 等. 糖尿病及急性冠状动脉综合征患者ApoB与ApoA1比值测定的临床意义[J]. 临床血液学杂志, 2013, 26(12): 837-840.
JIANG Weichao, ZHANG Detai, ZHANG Ke, et al. Clinical significance of serum apolipoprotein B/A1 ratio in patients with diabetes mellitus and acute coronary syndrome[J]. J Clin Hematol, 2013, 26(12): 837-840.
Citation: JIANG Weichao, ZHANG Detai, ZHANG Ke, et al. Clinical significance of serum apolipoprotein B/A1 ratio in patients with diabetes mellitus and acute coronary syndrome[J]. J Clin Hematol, 2013, 26(12): 837-840.

糖尿病及急性冠状动脉综合征患者ApoB与ApoA1比值测定的临床意义

详细信息
    通讯作者: 张德太,E-mail:Detaizhangwh@163.com
  • 中图分类号: R587.1

Clinical significance of serum apolipoprotein B/A1 ratio in patients with diabetes mellitus and acute coronary syndrome

More Information
  • 目的:研究糖尿病及急性冠状动脉综合征(ACS)患者血清载脂蛋白B(ApoB)与载脂蛋白A1(ApoA1)比值的变化并探讨其临床意义。方法:从体检人群中筛选可排除诊断为糖尿病及ACS的受检者33例为对照组、从住院患者中筛选临床确诊的单纯糖尿病患者47例、无糖尿病的ACS患者101例及ACS并发糖尿病患者52例,收集临床资料并分别检测各组空腹血糖、血脂和高敏C反应蛋白(hsCRP)水平。结果:糖尿病组、ACS非糖尿病组、ACS并发糖尿病组ApoB/ApoA1比值显著高于对照组(0.86±0.18、0.87±0.20、0.89±0.23):(0.76±0.15),均P<0.05。但3个患病组之间ApoB/ApoA1比值差异无统计学意义。高ApoB/ApoA1组(上4分位组)与低ApoB/ApoA1比较,BMI、FPG、TG、TC、LDL-C、hsCRP水平,糖尿病、高血压及ACS患病率均显著升高,而HDL-C水平则无显著变化。ROC曲线显示,ApoB/ApoA1较LDL-C具有更好的ACS诊断性能。结论:ApoB/ApoA1比值能较准确、灵敏地反映从糖尿病到ACS病程中脂代谢紊乱,并可用于对糖尿病预后及ACS发病风险的评估。
  • 加载中
  • [1]

    PETER W R,HERIBERT S.Diabetics with acute coronary syndrome:advances,challenges,and uncertainties[J].Eur Heart J,2010,31:2971-2973.

    [2]

    RUSSELL M,SILVERMAN A,FLEG J L,et al.Achieving lipid targets in adults with type 2 diabetes:The stop atherosclerosis in native diabetics study[J].J Clin Lipidol,2010,4:435-443.

    [3]

    LAKSHMAN R,FOROUHI N G,SHARP S J,et al.Early age at menarche associated with cardiovascular disease and mortality[J].J Clin Endocrinol Metab,2009,94:4953-4960.

    [4]

    SKURK T,ALBERTI-HUBER C,HERDER C,et al.Relationship between adipocyte size and adipokine expression and secretion[J].J Clin Endocrinol Metab,2007,92:1023-1033.

    [5]

    DEAN G K.Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease[J].Mayo Clin Proc,2009,84:345-352.

    [6]

    MILLER M.Lipid levels in the post-acute coronary syndrome setting:Destabilizing another myth?[J].J Am Coll Cardiol,2008,51:1446-1447.

    [7]

    刘晓辉,吴鹤,孙玉兰.急性心肌梗死早期的血脂分析[J].中国医师进修杂志,2006,29(4):52-53.

    [8]

    TASKINEN M R,BARTER P J,EHNHOLM C,et al.Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes[J].Diabetologia,2010,53:1846-1855.

    [9]

    VALENSI P,PICARD S.Lipids,lipid-lowering therapy and diabetes complications[J].Diabetes Metab,2011,37:15-24.

    [10]

    JAANA L,JOUKO S,GEORG A,et al.Apolipoprotein A-I,apolipoprotein B,and apolipoprotein B/apolipoprotein A-I ratio:Reference intervals compared with values in different pathophysiological conditions from the FINRISK 2007 study[J].Clinica Chimica Acta,2011,412:1146-1150.

  • 加载中
计量
  • 文章访问数:  93
  • PDF下载数:  82
  • 施引文献:  0
出版历程
收稿日期:  2013-04-07

目录